Gilead’s Revenue Is Accelerating, But are its Acquisitions Worth the Cost?
Gilead Sciences, Inc. (NASDAQ:GILD) delivered its strongest commercial momentum in several years during fiscal Q2 2026, with growth extending across HIV, oncology, and liver disease.







